Sol-Gel Technologies is an experienced dermatology company developing advanced treatments for patients with rare skin conditions.

Sep 30, 2024 · Sol-Gel reported a net loss of $0.4 million for the third quarter of 2024 and loss of $0.01 per basic and diluted share, compared to a net loss of $5.7 million and a loss of $0.21 …

May 16, 2024 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, …

Jul 12, 2024 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, …

Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-gel.com. July 27, 2021. Accessed August 22, 2023. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel …

Jun 28, 2021 · Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be …

Jan 27, 2023 · Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if …

Jan 27, 2023 · Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, …

Sol-Gel Technologies is an experienced dermatology company that is leveraging innovative approaches to develop advanced treatments for patients with severe skin conditions.

Sol-Gel’s marks and logos and all other proprietary identifiers used by Sol-Gel in connection with the Site (“Sol-Gel’s Trademarks”) are all trademarks and/or trade names of Sol-Gel, whether …